Pancreatic Adenocarcinoma
Personalized vaccine induces durable immune response in advanced kidney cancer
A personalized vaccine demonstrated the potential to induce long-lasting immune response among people with advanced kidney cancer, according to results of a phase 1 trial.
Zenocutuzumab exhibits efficacy in NRG1 fusion-positive cancers
Zenocutuzumab exhibited efficacy among patients with NRG1 fusion-positive cancers, according to phase 2 data published in The New England Journal of Medicine.
FDA approves therapies for lung, pancreatic cancers
The FDA approved two oncology therapies for treatment of certain patients with lung cancer or pancreatic cancer.
AI model highly accurate in differentiating pancreatic cystic, solid lesions on ultrasound
PHILADELPHIA — An AI model achieved high accuracy in detecting and distinguishing between cystic and solid pancreatic focal lesions during endoscopic ultrasound procedures, according to data presented at the ACG Annual Scientific Meeting.
Framework identifies yearly screening candidates at high risk for pancreatic cancer
A consortium recommended classifying people with a high risk for pancreatic cancer into subtypes based on family history and germline variants, according to findings published in Journal of the National Comprehensive Cancer Network.
Eryaspase regimen safe, may benefit certain patients with advanced pancreatic cancer
A study of eryaspase added to chemotherapy did not meet its primary endpoint of improved OS among patients with advanced pancreatic cancer, according to a presentation at ASCO Gastrointestinal Cancers Symposium.
FDA grants orphan drug designation to multitargeted T-cell therapy for pancreatic cancer
The FDA granted orphan drug designation to MT-601, an investigational T-cell immunotherapy, for treatment of advanced or metastatic pancreatic adenocarcinoma.
FDA clears IND application for CAR T-cell therapy targeting gastric, pancreatic cancers
The FDA cleared an investigational new drug application for CT041, a chimeric antigen receptor T-cell therapy for the treatment of adenocarcinoma of the stomach, gastroesophageal junction or pancreas.